Affimed’s (AFMD) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Affimed (NASDAQ:AFMD) in a research report released on Friday morning,Benzinga reports. They currently have a $10.00 price target on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Affimed in a research report on Monday, September 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $16.00.

Affimed Stock Performance

Shares of Affimed stock opened at $3.48 on Friday. The business’s fifty day moving average price is $3.49 and its 200 day moving average price is $4.51. Affimed has a twelve month low of $2.92 and a twelve month high of $8.95. The company has a current ratio of 2.71, a quick ratio of 2.71 and a debt-to-equity ratio of 0.13.

Affimed (NASDAQ:AFMD) last released its quarterly earnings data on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.09). The firm had revenue of $0.17 million during the quarter, compared to analyst estimates of $1.67 million. Affimed had a negative net margin of 7,836.26% and a negative return on equity of 165.35%. As a group, equities analysts expect that Affimed will post -4.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Affimed

Large investors have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. boosted its position in Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after buying an additional 15,108 shares during the last quarter. Intellectus Partners LLC boosted its holdings in Affimed by 12.2% in the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 10,250 shares during the last quarter. FMR LLC grew its stake in Affimed by 30.0% during the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 4,086 shares in the last quarter. Jane Street Group LLC purchased a new stake in Affimed during the 3rd quarter worth approximately $44,000. Finally, Choreo LLC acquired a new position in shares of Affimed in the 2nd quarter valued at approximately $54,000. 30.82% of the stock is owned by institutional investors and hedge funds.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.